Switching of oral anticoagulants in atrial fibrillation: a cohort study using Australian general practice data

References

• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021.
   Google Scholar
• Morillo CA, Banerjee A, Perel P, et al. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017;14(3):195–203.
   Google Scholar
• Wodchis WP, Bhatia RS, Leblanc K, et al. A review of the cost of atrial fibrillation. Value Health. 2012;15(2):240–248.
   Google Scholar
• Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2020;16(2):217–221.
   Google Scholar
• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858.
   Google Scholar
• Global Burden of Disease Study 2019 (GBD 2019). Seattle: WA: Institute for Health Metrics and Evaluation (IHME), University of Washington; [ Available from: http://ghdx.healthdata.org/gbd-results-tool. Accessed 2020 Oct 23.
   Google Scholar
• Freedman B, Potpara TS, Lip GYH. Stroke prevention in atrial fibrillation. Lancet. 2016;388(10046):806–817.
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrialfFibrillation patients. Stroke. 2018;49(12):2933–2944.
   Google Scholar
• Alamneh EA, Chalmers L, Bereznicki LR. The Tasmanian atrial fibrillation study: transition to direct oral anticoagulants 2011-2015. Cardiovasc Ther. 2017;35(3):e12254.
   Google Scholar
• Bezabhe WM, Bereznicki LR, Radford J, et al. Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation. Eur J Clin Invest. 2020;51(5):e13457.
   Google Scholar
• Bezabhe W, Bereznicki L, Radford J, et al. Ten-year trends in the use of oral anticoagulants in Australian general practice patients with atrial fibrillation. Front Pharmacol. 2021;12:586370.
   Google Scholar
• Kefale AT, Peterson GM, and Bezabhe WM, et al. Switching of oral anticoagulants in patients with non-valvular atrial fibrillation: a narrative review. Br J Clin Pharmacol. 2022;88(2):514–534.
   Google Scholar
• Hellfritzsch M, Husted SE, Grove EL, et al., Treatment changes among users of non-vitamin K antagonist oral anticoagulants in arial fibrillation. Basic Clin Pharmacol Toxicol. 120(2): 187–194. 2017.
   Google Scholar
• Hohnloser SH, Basic E, Nabauer M. Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study. Thromb Haemost. 2019;119(6):882–893.
   Google Scholar
• van Miert JHA, Kooistra HAM, Veeger NJGM, et al. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: little to GAInN. Thromb Res. 2020;190:69–75.
   Google Scholar
• Caldeira D, Costa J, Ferreira JJ, et al. Thromboembolic risk in the initiation, switch and interruption/re-initiation of oral anticoagulants: do newcomers improve outcomes? Insights from a meta-analysis of RCTs. Int J Cardiol. 2014;177(1):117–119.
   Google Scholar
• Feng X, Sambamoorthi U, Innes K, et al. Healthcare utilization and expenditures in working-age adults with atrial fibrillation: the effect of switching from warfarin to non-vitamin K oral anticoagulants. Am J Cardiovasc Drugs. 2018;18(6):513–520.
   Google Scholar
• MedicineInsight Data Book version 3.0 Sydney; June 2020.
   Google Scholar
• Busingye D, Gianacas C, Pollack A, et al. Data resource profile: medicineInsight, an Australian national primary health care database. Int J Epidemiol. 2019;48:1741–h.
   Google Scholar
• Perreault S, de Denus S, White-Guay B, et al., Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation. Pharmacotherapy. 40(1): 40–54. 2020.
   Google Scholar
• The Royal Australian College of General Practitioners. Standards for general practices. East Melbourne, Vic: RACGP; 2020.
   Google Scholar
• Australian Bureau of Statistics. Australian statistical geography standard. 2019.
   Google Scholar
• Australian Bureau of Statistics. Census of population and housing: socio-economic Indexes for Areas (SEIFA). Canberra; 2016.
   Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272.
   Google Scholar
• O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258–3264.
   Google Scholar
• Wilke T, Groth A, Fuchs A, et al. Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large sample of 38,076 German patients. Eur J Clin Pharmacol. 2017;73(11):1437–1447.
   Google Scholar
• Alalwan AA, Voils SA, Hartzema AG. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74(16):1237–1244.
   Google Scholar
• Fosbol EL, Vinding NE, Lamberts M, et al., Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation. Europace. 20(6): e78–e86. 2018.
   Google Scholar
• Fralick M, Colacci M, Schneeweiss S, et al. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med. 2020;172(7):463–473.
   Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.
   Google Scholar
• Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: american College of Chest Physicians Evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6 Suppl):160s–98s.
   Google Scholar
• Sansone RA, Sansone LA. Warfarin and antidepressants: happiness without hemorrhaging. Psychiatry (Edgmont). 2009;6(7):24–29.
   Google Scholar
• NHFA CSANZ Atrial Fibrillation Guideline Working Group, Brieger D, Amerena J, Amerena J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ. 2018;27(10):1209–1266.
   Google Scholar